Compare ANET & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANET | AMGN |
|---|---|---|
| Founded | 2004 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.1B | 188.0B |
| IPO Year | 2014 | 2000 |
| Metric | ANET | AMGN |
|---|---|---|
| Price | $151.87 | $346.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 17 | 20 |
| Target Price | $173.71 | ★ $348.05 |
| AVG Volume (30 Days) | ★ 6.0M | 2.3M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.87% |
| EPS Growth | 23.32 | ★ 88.23 |
| EPS | 2.75 | ★ 14.23 |
| Revenue | $9,005,700,000.00 | ★ $25,424,000,000.00 |
| Revenue This Year | $29.10 | $4.97 |
| Revenue Next Year | $21.80 | $2.49 |
| P/E Ratio | $53.65 | ★ $24.66 |
| Revenue Growth | ★ 28.60 | 8.83 |
| 52 Week Low | $66.59 | $265.66 |
| 52 Week High | $164.94 | $391.29 |
| Indicator | ANET | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.95 | 44.10 |
| Support Level | $138.18 | $344.95 |
| Resistance Level | $163.81 | $353.25 |
| Average True Range (ATR) | 5.59 | 7.53 |
| MACD | 3.00 | 0.38 |
| Stochastic Oscillator | 99.16 | 52.25 |
Arista Networks is a networking equipment provider that mainly sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three-quarters of its sales from North America.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.